{"id":49974,"date":"2025-12-04T20:45:29","date_gmt":"2025-12-04T12:45:29","guid":{"rendered":"https:\/\/flcube.com\/?p=49974"},"modified":"2025-12-04T20:45:30","modified_gmt":"2025-12-04T12:45:30","slug":"transthera-tinengotinib-cholangiocarcinoma-priority-review-china","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=49974","title":{"rendered":"TransThera Tinengotinib Cholangiocarcinoma Priority Review China"},"content":{"rendered":"\n<p><strong>TransThera Sciences (Nanjing) Inc.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/2617:HKG\">HKG: 2617<\/a>) announces that <strong>Tinengotinib tablets<\/strong> have been included in the <strong>List of Products for Priority Review<\/strong> by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) of China, for the treatment of adults with unresectable advanced or metastatic <strong>cholangiocarcinoma<\/strong> (CCA).<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-milestone-amp-drug-profile\">Regulatory Milestone &amp; Drug Profile<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Attribute<\/th><th>Details<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>TransThera Sciences (Nanjing) Inc. (HKG: 2617)<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>Tinengotinib tablets<\/td><\/tr><tr><td><strong>Regulatory Status<\/strong><\/td><td>Included in CDE Priority Review List (China)<\/td><\/tr><tr><td><strong>Target Indication<\/strong><\/td><td>Unresectable advanced or metastatic cholangiocarcinoma (post-systemic and FGFR inhibitor therapy)<\/td><\/tr><tr><td><strong>Previous Designation<\/strong><\/td><td>Breakthrough Therapy Designation (NMPA) for CCA<\/td><\/tr><tr><td><strong>Drug Class<\/strong><\/td><td>Oral small-molecule kinase inhibitor<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-mechanism-of-action-amp-unique-targeting\">Mechanism of Action &amp; Unique Targeting<\/h2>\n\n\n\n<p>Tinengotinib is a multi-kinase inhibitor targeting three key pathways:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>FGFR\/VEGFR<\/strong>: Inhibits fibroblast growth factor and vascular endothelial growth factor receptors, blocking tumor angiogenesis and growth signals<\/li>\n\n\n\n<li><strong>JAK<\/strong>: Suppresses Janus kinase-mediated inflammatory and proliferative signaling<\/li>\n\n\n\n<li><strong>Aurora kinases<\/strong>: Interferes with mitotic spindle formation, inducing cell cycle arrest<\/li>\n<\/ul>\n\n\n\n<p>This multi-target approach addresses the heterogeneity of cholangiocarcinoma and may overcome resistance to single-agent FGFR inhibitors.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-context-amp-competitive-landscape\">Market Context &amp; Competitive Landscape<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Market Parameter<\/th><th>Value\/Insight<\/th><\/tr><\/thead><tbody><tr><td><strong>Cholangiocarcinoma Incidence (China)<\/strong><\/td><td>~60,000 new cases annually; second most common hepatobiliary malignancy<\/td><\/tr><tr><td><strong>Target Population<\/strong><\/td><td>FGFR inhibitor-refractory patients represent ~30% of advanced CCA cases<\/td><\/tr><tr><td><strong>Current Standard of Care<\/strong><\/td><td>Limited options after FGFR inhibitor failure; no approved third-line therapies<\/td><\/tr><tr><td><strong>Pipeline Landscape<\/strong><\/td><td>Tinengotinib is one of three late-stage CCA drugs in China with Breakthrough Therapy status<\/td><\/tr><tr><td><strong>Commercial Potential<\/strong><\/td><td>Analysts project peak China sales of <strong>\u00a51.2-1.5 billion<\/strong> (\u2248\u202fUS$170-210 million) if approved<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-outlook-amp-development-timeline\">Strategic Outlook &amp; Development Timeline<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Priority Review Impact<\/strong>: CDE review timeline expected to be reduced from 12-18 months to 6-9 months<\/li>\n\n\n\n<li><strong>Clinical Data<\/strong>: Based on Phase II data showing <strong>objective response rate of 22%<\/strong> and <strong>median PFS of 5.8 months<\/strong> in heavily pre-treated FGFR inhibitor-refractory patients<\/li>\n\n\n\n<li><strong>Global Strategy<\/strong>: TransThera plans to file for FDA Fast Track designation in H1\u202f2026, leveraging China data<\/li>\n\n\n\n<li><strong>Manufacturing<\/strong>: Commercial-scale production validated; ready for market launch upon approval<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding Tinengotinib&#8217;s regulatory review timeline, market potential, and clinical development plans. Actual results may differ due to regulatory, competitive, and clinical uncertainties.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/2025120301250_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2025120301250_c.\"><\/object><a id=\"wp-block-file--media-7bec2c80-6f87-430e-ae15-bec46eb6872e\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/2025120301250_c.pdf\">2025120301250_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/2025120301250_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-7bec2c80-6f87-430e-ae15-bec46eb6872e\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>TransThera Sciences (Nanjing) Inc. (HKG: 2617) announces that Tinengotinib tablets have been included in the&#8230;<\/p>\n","protected":false},"author":1,"featured_media":49978,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[4181,80,33,601],"class_list":["post-49974","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-hkg-2617","tag-priority-reviews","tag-tkis-egfr-vegf-btk-etc","tag-transthera-sciences"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>TransThera Tinengotinib Cholangiocarcinoma Priority Review China - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"TransThera Sciences (Nanjing) Inc. (HKG: 2617) announces that Tinengotinib tablets have been included in the List of Products for Priority Review by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) of China, for the treatment of adults with unresectable advanced or metastatic cholangiocarcinoma (CCA).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=49974\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"TransThera Tinengotinib Cholangiocarcinoma Priority Review China\" \/>\n<meta property=\"og:description\" content=\"TransThera Sciences (Nanjing) Inc. (HKG: 2617) announces that Tinengotinib tablets have been included in the List of Products for Priority Review by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) of China, for the treatment of adults with unresectable advanced or metastatic cholangiocarcinoma (CCA).\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=49974\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-12-04T12:45:29+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-12-04T12:45:30+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/0403-2.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49974#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49974\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"TransThera Tinengotinib Cholangiocarcinoma Priority Review China\",\"datePublished\":\"2025-12-04T12:45:29+00:00\",\"dateModified\":\"2025-12-04T12:45:30+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49974\"},\"wordCount\":356,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49974#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/0403-2.webp\",\"keywords\":[\"HKG: 2617\",\"Priority reviews\",\"TKIs (EGFR VEGF BTK etc.)\",\"TransThera Sciences\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=49974#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49974\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=49974\",\"name\":\"TransThera Tinengotinib Cholangiocarcinoma Priority Review China - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49974#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49974#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/0403-2.webp\",\"datePublished\":\"2025-12-04T12:45:29+00:00\",\"dateModified\":\"2025-12-04T12:45:30+00:00\",\"description\":\"TransThera Sciences (Nanjing) Inc. (HKG: 2617) announces that Tinengotinib tablets have been included in the List of Products for Priority Review by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) of China, for the treatment of adults with unresectable advanced or metastatic cholangiocarcinoma (CCA).\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49974#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=49974\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49974#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/0403-2.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/0403-2.webp\",\"width\":1080,\"height\":608,\"caption\":\"TransThera Tinengotinib Cholangiocarcinoma Priority Review China\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49974#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"TransThera Tinengotinib Cholangiocarcinoma Priority Review China\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"TransThera Tinengotinib Cholangiocarcinoma Priority Review China - Insight, China&#039;s Pharmaceutical Industry","description":"TransThera Sciences (Nanjing) Inc. (HKG: 2617) announces that Tinengotinib tablets have been included in the List of Products for Priority Review by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) of China, for the treatment of adults with unresectable advanced or metastatic cholangiocarcinoma (CCA).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=49974","og_locale":"en_US","og_type":"article","og_title":"TransThera Tinengotinib Cholangiocarcinoma Priority Review China","og_description":"TransThera Sciences (Nanjing) Inc. (HKG: 2617) announces that Tinengotinib tablets have been included in the List of Products for Priority Review by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) of China, for the treatment of adults with unresectable advanced or metastatic cholangiocarcinoma (CCA).","og_url":"https:\/\/flcube.com\/?p=49974","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-12-04T12:45:29+00:00","article_modified_time":"2025-12-04T12:45:30+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/0403-2.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=49974#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=49974"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"TransThera Tinengotinib Cholangiocarcinoma Priority Review China","datePublished":"2025-12-04T12:45:29+00:00","dateModified":"2025-12-04T12:45:30+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=49974"},"wordCount":356,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=49974#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/0403-2.webp","keywords":["HKG: 2617","Priority reviews","TKIs (EGFR VEGF BTK etc.)","TransThera Sciences"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=49974#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=49974","url":"https:\/\/flcube.com\/?p=49974","name":"TransThera Tinengotinib Cholangiocarcinoma Priority Review China - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=49974#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=49974#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/0403-2.webp","datePublished":"2025-12-04T12:45:29+00:00","dateModified":"2025-12-04T12:45:30+00:00","description":"TransThera Sciences (Nanjing) Inc. (HKG: 2617) announces that Tinengotinib tablets have been included in the List of Products for Priority Review by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) of China, for the treatment of adults with unresectable advanced or metastatic cholangiocarcinoma (CCA).","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=49974#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=49974"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=49974#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/0403-2.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/0403-2.webp","width":1080,"height":608,"caption":"TransThera Tinengotinib Cholangiocarcinoma Priority Review China"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=49974#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"TransThera Tinengotinib Cholangiocarcinoma Priority Review China"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/0403-2.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/49974","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=49974"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/49974\/revisions"}],"predecessor-version":[{"id":49979,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/49974\/revisions\/49979"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/49978"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=49974"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=49974"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=49974"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}